Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cryolife (NYSE: CRY), Compugen Ltd (NASDAQ: CGEN) and Juno Therapeutics (NASDAQ: JUNO).
Cryolife (NYSE: CRY)
In a report released yesterday, Jason Mills from Canaccord Genuity reiterated a Buy rating on Cryolife (NYSE: CRY), with a price target of $23.50. The company’s shares opened today at $18.25.
According to TipRanks.com, Mills is a 5-star analyst with an average return of 12.0% and a 68.7% success rate. Mills covers the Healthcare sector, focusing on stocks such as Integer Holdings Corporation, Tactile Systems Technology, and Trivascular Technologies.
Cryolife has an analyst consensus of Moderate Buy, with a price target consensus of $23.50.
Compugen Ltd (NASDAQ: CGEN)
FBR Capital analyst Vernon Bernardino reiterated a Buy rating on Compugen Ltd (NASDAQ: CGEN) today and set a price target of $14. The company’s shares opened today at $4.35.
Bernardino wrote:
“We think the inventory of novel assets Compugen is amassing that represent future licensing opportunities continues to be underappreciated. For example, we note that compared to their nascent stage a year ago, CGEN now has advanced two wholly-owned internal assets into IND stage (COM701 and COM902), both of which target novel immune checkpoint proteins where CGEN leads the industry in characterizing. We remind investors that CGEN also has two immune checkpoint targets (internally designated for competitive purposes as CGEN-15001T and CGEN-15022) that CGEN’s partner, Bayer, has advanced into product candidate screening and lead selection activities. We remain convinced that CGEN’s broad discovery capabilities have strong potential to generate a pipeline of valuable, first-in-class assets, and we look for CGEN to advance into at least one high-value collaboration by year-end 2017. With the shares currently trading near 52-week lows, we think CGEN prices would be attractive to new investors.”
According to TipRanks.com, Bernardino is ranked 0 out of 5 stars with an average return of -6.8% and a 30.0% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Actinium Pharmaceuticals, and Conatus Pharmaceuticals.
Compugen Ltd has an analyst consensus of Moderate Buy, with a price target consensus of $11.50.
Juno Therapeutics (NASDAQ: JUNO)
FBR Capital analyst Edward White reiterated a Hold rating on Juno Therapeutics (NASDAQ: JUNO) yesterday. The company’s shares opened today at $25.06.
According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -5.0% and a 41.5% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and RXi Pharmaceuticals Corp.
Currently, the analyst consensus on Juno Therapeutics is Moderate Buy and the average price target is $29.67, representing a 18.4% upside.
In a report issued on May 4, J.P. Morgan also reiterated a Hold rating on the stock with a $31 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.